ChinesevaccinemarketcompetitionanalysisVaccinesdonotknowalotoffriendsintheChinesevaccinemarketiscurrentlythesituationathandinthemuddleofdoingthings,thisisnotagoodhabit,becauseifchangesintheenvironmentsurroundingthesale,andweusedtoandinaccordancewithpastsalesmarketingpractices,then,theeffectofthevaccinewillbegreatlyreducedsales.Therefore,tounderstandsimpleChinesevaccinenecessaryenvironmentisnecessary.Currently,IbelievethatSHILi-chen:Chinesehumanvaccinefromtheuse,managementandsalesbasicallydividedintotwocategories:Aclassofseedlings,thatcountwithfreeseedlings,thestateplanstopurchase,salespracticesledbythegovernment,vaccinemanufacturersforproductionandtender,afterwinningcanonlyberesponsibleforproductionandsupply.Twotypesofvaccine:theenterprise-ledmarketing,salespracticesandgovernmentregulationduringtransport.2006-2008,theglobalvaccinemarkethasgrownrapidly,significantlyhigherthanthelevelofthepharmaceuticalmarket,beginningin2004,thedomesticvaccinemarketannualgrowthrateof25percentfrom2006to2008,jumpedfrom3.1billionto60billion---本文于网络，仅供参考，勿照抄，如有侵权请联系删除---yuan,compoundannualgrowthrateof39%,farexceedingtheinternationalmarketinrecentyearsthegrowthrateof29%in2008,thenationalpharmaceuticalindustryrealizedsalesincomeof866.6billionyuan,whichisequivalenttothedomesticvaccineindustry,thepharmaceuticalindustryinsalesof0.7%,farbelowtheworldlevelof2.5%,showingthatChina’svaccineindustry,thereisstillmuchroomforgrowth.ISHILi-chensaid:perspectivefromthecompetitivesituation,isbasicallyaboutthethreeforcesoftheChinesevaccinemarketsales:Thefirstforces:thenationalteamnationalteamiscurrentlythemainforceofChina’svaccinemarket,whichistheleaderoftheHealthandMedicinesGroup.IntheHealthGroupisthelargestproductionofvaccinesandbloodproductssupplier,underthejurisdictionofBei激ng,Shanghai,Wuhan,Chengdu,Changchun,Lanzhou,andthesixInstituteofBiologicalProducts,vaccinesandbloodproductsintheRD,faraheadofotherdomesticcompanies.andhasthelargestlistedcompaniesTiantanBiologicalProductsBiologicalProducts(600,161.2009September16,theStateCouncil,State-ownedBoardofficialwebsite,bytheStateCouncil,ChinaPharmaceuticalGroupCorporation(hereinafterreferredtoasbio----本文于网络，仅供参考，勿照抄，如有侵权请联系删除---technologyandChinaNationalPharmaceuticalGroupCorporation(hereinafterreferredtoastheHealthGrouptoimplementthejointreorganizationintheHealthGroupinresearchandbiologicalproductshavetradeadvantages,andthepresentMedicinesGrouptocreatescience,industryandtradeintegrationpattern,inJohnson’sstrengthsmakeupforthelackofMedicinesGroup;theotherhand,Sinopharmwithcoldchainanddistributioncapabilities,butalsoforbloodproductsintheHealthGroupprovidesacomplementaryoutputservices.Thesecondinfluence:foreignteams,mainlyonbehalfofGlaxoSmithKline,SanofiPasteur,Merck,Pfizer(Wyeth,Novartis,etc.haveenteredthedomesticmarket,companieswithannualsalesof100million8rangingfromonehundredmillionyuan,ofwhichGSKsalesinChina,thelargestrevenuein2008wasabout$800millioncapitalstrengthoftheseforeignteams,RDinvestment,innovationability,highbrandpremium,mainlytoseizetheChinesehigh-vaccinemarket,entrenchedinthedomesticmarket,secondandthirdtiercitiespresenttherelevantnationalvaccinepolicyteamalotofinfluenceonforeigninvestment,suchasGSKandPasteurHIB(bHibvaccinein2010becausetheydonotmeetthenationalpha...